Estudo RECOVERY | Baricitinibe em pacientes hospitalizados com COVID-19.
5 Ago, 2022 | 16:50hComentário convidado: Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality – The Lancet
Conteúdos relacionados:
WHO recommends two new drugs to treat COVID-19 – World Health Organization
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine
Comentário no Twitter
New @TheLancet
The largest trial of baricitinib, a JAK-inhibitor drug repurposed via #AI data mining, reduced Covid mortality and the overall reduction consistent with 8 previous RCTs (~20%)https://t.co/5fHDBBvm3Q pic.twitter.com/GDFzcU26H6— Eric Topol (@EricTopol) July 29, 2022
Sob licença de Creative Commons Attribution (CC BY 4.0)